Abstrakt

Przypisy

• 1. Arends J., Bodoky G., Bozzetti F., Fearon K., Muscaritoli M., SelgaG., van Bokhorst-de van der Schueren M.A., von Meyenfeldt M.,Zürcher G., Fietkau R., Aulbert E., Frick B., Holm M., Kneba M., MestromH.J., Zander A.: ESPEN Guidelines on Enteral Nutrition: Nonsurgicaloncology. Clin. Nutr., 2006; 25: 245-259
  Google Scholar
• 2. Argilés J.M., López-Soriano F.J.: The role of cytokines in cancercachexia. Med. Res. Rev., 1999; 19: 223-248
  Google Scholar
• 3. Argilés J.M., Olivan M., Busquets S., López-Soriano F.J.: Optimalmanagement of cancer anorexia-cachexia syndrome. Cancer Manag.Res., 2010; 2: 27-38
  Google Scholar
• 4. Asher V., Lee J., Bali A.: Preoperative serum albumin is an independentprognostic predictor of survival in ovarian cancer. Med.Oncol., 2012; 29: 2005-2009
  Google Scholar
• 5. Bachmann J., Heiligensetzer M., Krakowski-Roosen H., BüchlerM.W., Friess H., Martignoni M.E:. Cachexia worsens prognosis inpatients with resectable pancreatic cancer. J. Gastrointest. Surg.,2008; 12: 1193-1201
  Google Scholar
• 6. Balkwill F., Osborne R., Burke F., Naylor S., Talbot D., Durbin H.,Tavernier J., Fiers W.: Evidence for tumour necrosis factor/cachectinproduction in cancer. Lancet, 1987; 2: 1229-1232
  Google Scholar
• 7. Beck S.A., Tisdale M.J.: Lipid mobilising factors specifically associatedwith cancer cachexia. Br. J. Cancer, 1991; 63: 846-850
  Google Scholar
• 8. Benny Klimek M.E., Aydogdu T., Link M.J., Pons M., Koniaris L.G.,Zimmers T.A.: Acute inhibition of myostatin-family proteins preservesskeletal muscle in mouse models of cancer cachexia. Biochem.Biophys. Res. Commun., 2010; 391: 1548-1554
  Google Scholar
• 9. Bonetto A.., Penna F., Minero V.G., Reffo P., Costamagna D.,Bonelli G., Baccino F.M., Costelli P.: Glutamine prevents myostatinhyperexpression and protein hypercatabolism inducedin C2C12 myotubes by tumor necrosis factor-α. Amino Acids,2011; 40: 585-594
  Google Scholar
• 10. Bossola M., Pacelli F., Tortorelli A., Rosa F., Doglietto G.B.: Skeletalmuscle in cancer cachexia: the ideal target of drug therapy. Curr.Cancer Drug Targets, 2008; 4: 285-298
  Google Scholar
• 11. Bozzetti F., Arends J., Lundholm K., Micklewright A., ZurcherG., Muscaritoli M.: ESPEN Guidelines on Parenteral Nutrition: nonsurgicaloncology. Clin. Nutr., 2009; 28: 445-454
  Google Scholar
• 12. Bozzetti F., Mariani L.: Defining and classifying cancer cachexia:a proposal by the SCRINIO Working Group. J. Parenter. Enteral Nutr.,2009; 33: 361-367
  Google Scholar
• 13. Busquets S., Toledo M., Marmonti E., Orpí M., Capdevila E., BetancourtA., López-Soriano F.J., Argilés J.M.: Formoterol treatmentdownregulates the myostatin system in skeletal muscle of cachectictumour-bearing rats. Oncol. Lett., 2012; 3: 185-189
  Google Scholar
• 14. Cao D.X., Wu G.H., Zhang B., Quan Y.J., Wei J., Jin H., Jiang Y., YangZ.A.: Resting energy expenditure and body composition in patientswith newly detected cancer. Clin. Nutr., 2010; 29: 72-77
  Google Scholar
• 15. Capuano G., Gentile P.C., Bianciardi F., Tosti M., Palladino A., DiPalma M.: Prevalence and influence of malnutrition on quality of lifeand performance status in patients with locally advanced head andneck cancer before treatment. Support. Care Cancer, 2010; 18: 433-437
  Google Scholar
• 16. Colomer R., Moreno-Nogueira J.M., García-Luna P.P., García-PerisP., García-de-Lorenzo A., Zarazaga A., Quecedo L., del LlanoJ., Usa´nL., Casimiro C.: N-3 fatty acids, cancer and cachexia: a systematicreview of the literature. Br. J. Nutr., 2007; 97: 823-831
  Google Scholar
• 17. Cosper P.F., Leinwand L.A.: Myosin heavy chain is not selectivelydecreased in murine cancer cachexia. Int. J. Cancer, 2012;130: 2722-2727
  Google Scholar
• 18. Costelli P., Muscaritoli M., Bonetto A., Penna F., Reffo P., BossolaM., Bonelli G., Doglietto G.B., Baccino F.M., Rossi-Fanelli R.: Musclemyostatin signalling is enhanced in experimental cancer cachexia.Eur. J. Clin. Invest., 2008; 38: 531-538
  Google Scholar
• 19. Das S.K., Eder S., Schauer S., Diwoky C., Temmel H., Guertl B., GorkiewiczG., Tamilarasan K.P., Kumari P., Trauner M., Zimmermann R., VeselyP., Haemmerle G., Zechner R., Hoefler G.: Adipose triglyceride lipasecontributes to cancer-associated cachexia. Science, 2011; 333: 233-238
  Google Scholar
• 20. Deans D.A., Wigmore S.J., Gilmour H., Paterson-Brown S., RossJ.A., Fearon K.C.: Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophagealcancer. Br. J. Cancer, 2006; 95: 1568-1575
  Google Scholar
• 21. Deans C., Wigmore S., Paterson-Brown S., Black J., Ross J., FearonK.C.: Serum parathyroid hormone-related peptide is associated withsystemic inflammation and adverse prognosis in gastroesophagealcarcinoma. Cancer, 2005; 103: 1810-1818
  Google Scholar
• 22. Desport J.C., Gory-Delabaere G., Blanc-Vincent M.P., BachmannP., Béal J., Benamouzig R., Colomb V., Kere D., Melchior J.C., NitenbergG., Raynard B., Schneider S., Senesse P.: FNCLCC. Standards, optionsand recommendations for the use of appetite stimulants in oncology(2000). Br. J. Cancer, 2003; 89 (Suppl. 1): 98-100
  Google Scholar
• 23. Fearon K., Strasser F., Anker S.D., Bosaeus I., Bruera E., FainsingerR.L., Jatoi A., Loprinzi C., MacDonald N., Mantovani G., Davis M.,Muscaritoli M., Ottery F., Radbruch L., Ravasco P., Walsh D., WilcockA., Kaasa S., Baracos V.E.: Definition and classification of cancer cachexia:an international consensus. Lancet Oncol., 2011; 12: 489-495
  Google Scholar
• 24. Fouladiun M., Körner U., Bosaeus I., Daneryd P., HyltanderA., Lundholm K.G.: Body composition and time course changesin regional distribution of fat and lean tissue in unselected cancerpatients on palliative care – correlations with food intake,metabolism, exercise capacity, and hormones. Cancer, 2005; 103:2189-2198
  Google Scholar
• 25. Garcia J.M., Garcia-Touza M., Hijazi R.A., Taffet G., Epner D.,Mann D., Smith R.G., Cunningham G.R., Marcelli M.: Active ghrelinlevels and active to total ghrelin ratio in cancer-induced cachexia.J. Clin. Endocrynol. Metab., 2005; 90: 2920-2926
  Google Scholar
• 26. Glass D.J.: Signaling pathways perturbing muscle mass. Curr.Opin. Clin. Nutr. Metab. Care, 2010; 13: 225-229
  Google Scholar
• 27. Han H.Q., Zhou X., Mitch W.E., Goldberg A.L.: Myostatin/activinpathway antagonism: molecular basis and therapeutic potential. Int.J. Biochem. Cell Biol., 2013; 45: 2333-2347
  Google Scholar
• 28. Kotler D.P.: Cachexia. Ann. Intern. Med., 2000; 133: 622-634
  Google Scholar
• 29. Ladner K.J., Caligiuri M.A., Guttridge D.C.: Tumor necrosis factor-regulatedbiphasic activation of NF-κB is required for cytokineinducedloss of skeletal muscle gene products. J. Biol. Chem., 2003;278: 2294-2303
  Google Scholar
• 30. Laviano A., Meguid M.M., Inui A., Muscaritoli M., Rossi-FanelliF.: Therapy insight: Cancer anorexia-cachexia syndrome – whenall you can eat is yourself. Nat. Clin. Pract. Oncol., 2005; 2: 158-165
  Google Scholar
• 31. Lecker S.H., Solomon V., Mitch W.E., Goldberg A.L.: Muscleprotein breakdown and the critical role of the ubiquitin-proteasomepathway in normal and disease states. J. Nutr., 1999; 129:227S-237S
  Google Scholar
• 32. Leśniak W., Bała M., Jaeschke R., Krzakowski M.: Effects of megestrolacetate in patients with cancer anorexia-cachexia syndrome–asystematic review and meta-analysis. Pol. Arch. Med. Wewn., 2008;118: 636-644
  Google Scholar
• 33. Lochs H., Allison S.P., Meier R., Pirlich M., Kondrup J., SchneiderS., van den Berghe G., Pichard C.: Introductory to the ESPEN Guidelineson Enteral Nutrition: terminology, definitions and generaltopics. Clin. Nutr., 2006; 25: 180-186
  Google Scholar
• 34. MacFie J.: Ethical implications of recognizing nutritional supportas a medical therapy. Br. J. Surg., 1996; 83: 1567-1568
  Google Scholar
• 35. Makarenko I.G., Meguid M.M., Gatto L., Chen C., Ugrumov M.V.:Decreased NPY innervation of the hypothalamic nuclei in rats withcancer anorexia. Brain Res., 2003; 961: 100-108
  Google Scholar
• 36. Mantovani G.: Randomised phase III clinical trial of 5 differentarms of treatment on 332 patients with cancer cachexia. Eur. Rev.Med. Pharmacol. Sci., 2010; 14: 292-301
  Google Scholar
• 37. Marks D.L., Ling N., Cone R.D.: Role of the central melanocortinsystem in cachexia. Cancer Res., 2001; 61: 1432-1438
  Google Scholar
• 38. Oliff A., Defeo-Jones D., Boyer M., Martinez D., Kiefer D., VuocoloG., Wolfe A., Socher S.H.: Tumors secreting human TNF/cachectininduce cachexia in mice. Cell, 1987; 50: 555-563
  Google Scholar
• 39. Penna F., Minero V.G., Costamagna D., Bonelli G., Baccino F.M.,Costelli P.: Anti-cytokine strategies for the treatment of cancer-relatedanorexia and cachexia. Expert Opin. Biol. Ther., 2010; 10: 1241-1250
  Google Scholar
• 40. Pisters P.W., Brennan M.F.: Amino acid metabolism in humancancer cachexia. Annu. Rev. Nutr., 1990; 10: 107-132
  Google Scholar
• 41. Rubin H.: Cancer cachexia: its correlations and causes. Proc.Natl. Acad. Sci. USA, 2003; 100: 5384-5389
  Google Scholar
• 42. Tisdale M.J.: Cancer cachexia. Br. J. Cancer, 1991; 63: 337-342
  Google Scholar
• 43. Tisdale M.J.: Biology of cachexia. J. Natl. Cancer Inst., 1997; 89:1763-1773
  Google Scholar
• 44. Tisdale M.J.: The ‚cancer cachectic factor’. Support Care Cancer,2003; 11: 73-78
  Google Scholar
• 45. Tisdale M.J.: Cachexia in cancer patients. Nat. Rev. Cancer, 2002;2: 862-871
  Google Scholar
• 46. Trikha M., Corringham R., Klein B., Rossi J.F.: Targeted anti-interleukin-6monoclonal antibody therapy for cancer: a review of therationale and clinical evidence. Clin. Cancer Res., 2003; 9: 4653-4665
  Google Scholar

Pełna treść artykułu